Soligenix Inc (SNGX)

2.48
NASDAQ : Health Care
Prev Close 2.48
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.90 / 14.40
Avg Volume 33.60K
Exchange NASDAQ
Shares Outstanding 5.44M
Market Cap 14.95M
EPS -6.50
Div & Yield N.A. (N.A)

Latest News

Soligenix Announces Extension Of Development Agreement With Emergent BioSolutions

Soligenix Announces Extension Of Development Agreement With Emergent BioSolutions

Supported with NIAID Contract Funding of up to $24.7 million

Soligenix Advances Collaboration With IDT Biologika

Soligenix Advances Collaboration With IDT Biologika

Supported with NIAID Contract Funding of up to $24.7 million

Soligenix And SciClone Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis

Soligenix And SciClone Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis

Agreement Includes Greater China and Other East Asia Markets

Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs

Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs

Patents provide broad protection for the innate defense regulator technology platform

Soligenix Receives Additional BARDA And NIAID Funding To Advance Development Of OrbeShield® In GI ARS

Soligenix Receives Additional BARDA And NIAID Funding To Advance Development Of OrbeShield® In GI ARS

Awarded $634,000 in additional contract funding

Soligenix Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation

Soligenix Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation

ThermoVax® Development Expands into Pandemic Infectious Disease

OTCQX And OTCQB Companies To Present At 2016 Marcum MicroCap Conference

OTCQX And OTCQB Companies To Present At 2016 Marcum MicroCap Conference

OTC Markets Group, President and CEO R. Cromwell Coulson, will speak on panel "Understanding Reg A+ and the 'Mini IPO'"

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Awarded $3.2M to Conduct Preclincial Efficacy and Toxicology Studies

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Soligenix Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine

Awarded $4.3M to Support Manufacturing Activities

Soligenix Announces Issuance Of New Patents For Dusquetide

Soligenix Announces Issuance Of New Patents For Dusquetide

Patents provide broad protection, including composition of matter claims

Soligenix Announces Publication Of Preclinical Efficacy Results With Dusquetide In Infectious Disease

Soligenix Announces Publication Of Preclinical Efficacy Results With Dusquetide In Infectious Disease

Preclinical Results Supported by Recent Positive Phase 2 Clinical Trial

Soligenix Announces Recent Accomplishments And Year-End 2015 Financial Results

Soligenix Announces Recent Accomplishments And Year-End 2015 Financial Results

Highlighted by Revenues of $8.8 Million